Updates in the Management of Graft-Versus-Host Disease
Educating nurses in the identification of symptoms and the treatments available will increase the identification and early treatment of GVHD in patients.  Nurses are in a perfect position to include other team members to address the psychosocial and palliative/symptomatic care of patients with GVHD, both acute and chronic.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Implementation of a Hematology Outpatient Sepsis Alert Protocol
Quality initiatives directed at standardized clinical pathways for symptom management, and development for urgent cancer care tactics are becoming a standard in cancer care to help reduce sepsis and the need for acute care.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Palliative Care and Hematologic Malignancies: Can They Co-Exist?
Education on the use of palliative care resources is important to help hematology oncology clinicians potentially lessen the bias that may surround including “outsiders” in the care of their patients, thus allowing these patients and their caregivers to experience the benefits of this resource earlier in their care.
Category
  • Palliative Care
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Key Assessment and Evaluation Strategies After CAR T-Cell Therapy
The management of adverse effects, including toxicity from treatment as well as the education of patients and the coverage of these treatments by insurance are imperative to good clinical care of patients receiving these therapies.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
The Importance of Re-Vaccination After Cellular Therapy
Cellular therapies are associated with an increased infection risk, and vaccination in these survivors plays a critical role in lowering that risk. Clinicians need to be educated on the importance of vaccination in these survivors as well as the details of dosing and timing of vaccines to best protect this vulnerable population from vaccine-preventable diseases.
Category
  • Hematologic Malignancies
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Treatment Decisions in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The use of targeted therapies as a preferred treatment approach for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly transformed the treatment landscape of relapsed/refractory disease. The benefit/risk of continuous vs.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing Treatment for Relapsed/Refractory Mantle Cell Lymphoma
The selection of optimal second-line therapy for mantle cell lymphoma (MCL) depends on the age and fitness of the patients as well as the eligibility for transplant or CAR T-cell therapy. In the absence of standard management, patients with relapsed/refractory MCL should be referred for participation in prospective clinical trials investigating novel treatment regimens.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Debate: Transplant vs. CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Educating clinicians about the recent clinical advances and the benefits/risks associated with the use of transplant and CAR T-cell therapy can help them to make informed clinical decisions for individual patients.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
ECHELON-1: Do Updated Results Change the First-Line Treatment of Stage III-IV Classical Hodgkin Lymphoma?
An awareness of the updated safety and efficacy results from the ECHELON-1 trial will help clinicians determine how to optimally incorporate BV-AVD regimen as fist-line therapy in appropriately selected patients with stage III-IV classical Hodgkin lymphoma.
Category
  • Hodgkin Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Familial/Genetic Leukemia Syndromes: Impact on Patient Care
Clinicians need education regarding which patients with leukemia are candidates for genetic counseling and testing and how the management of patients with known germline mutations is affected. This knowledge will help clinicians provide these patients with optimal care.
Category
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Chronic Myelogenous Leukemia
  • Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages